Harpoon Therapeutics Announced Confirmed Response Rate 35% (11/31), Across All Tumor Types And Patient Cohorts Treated With 1 Mg Priming Dose, Including Three Confirmed, Complete Responses In Phase 1/2 Clinical Trial of T Cell Engager HPN328
Portfolio Pulse from Charles Gross
Harpoon Therapeutics, Inc. (NASDAQ:HARP) announced updated interim data from its Phase 1/2 clinical trial of T cell engager HPN328, showing a confirmed response rate of 35% across all tumor types and patient cohorts treated with a 1 mg priming dose. The trial is nearing completion and the company is on track to select Phase 2 doses by the end of 2023.
October 21, 2023 | 6:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harpoon Therapeutics' Phase 1/2 clinical trial of HPN328 shows promising results, which could potentially boost investor confidence and the company's stock price.
The positive interim data from Harpoon Therapeutics' Phase 1/2 clinical trial of HPN328 indicates progress in the company's product pipeline. This could potentially lead to increased investor confidence in the company's future prospects, which could in turn positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100